Stockscreener 앱 받기
1.285
3.00%
0.035
Rani Therapeutics Holdings Inc 주식(RANI)의 최신 뉴스
Published on: 2026-02-13 18:32:35 - baoquankhu1.vn
Is Rani Therapeutics Holdings Inc. stock near bottom after decline2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Income Plays: What is the next catalyst for Rani Therapeutics Holdings IncWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Published on: 2026-02-02 11:44:32 - baoquankhu1.vn
What is the next catalyst for Rani Therapeutics Holdings IncWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit - simplywall.st
Rani Therapeutics promotes Alireza Javadi to chief technical officer By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings, Inc. Announces Promotion of Alireza Javadi to Chief Technical Officer - marketscreener.com
Rani Therapeutics announces the promotion of Alireza Javadi, Ph.D. to chief technical officer - marketscreener.com
Rani Therapeutics Names Alireza Javadi Chief Technical Officer - Nasdaq
Rani Therapeutics promotes Alireza Javadi to chief technical officer - Investing.com
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - The Manila Times
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bear Alert: Does CompoSecure Inc Equity Warrant stock have upside surprise potential2025 Sector Review & Daily Stock Trend Watchlist - baoquankhu1.vn
Published on: 2026-01-24 03:15:13 - baoquankhu1.vn
AI Stocks: Does XBiotech Inc offer margin of safety2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY) - The Globe and Mail
Rani Therapeutics finalizes governance and capital structure changes - MSN
Targets Report: Can Rani Therapeutics Holdings Inc navigate macro headwindsJuly 2025 Chart Watch & Consistent Return Investment Signals - baoquankhu1.vn
Price Action: Can Rani Therapeutics Holdings Inc navigate macro headwinds2025 Technical Patterns & Community Supported Trade Ideas - baoquankhu1.vn
HOKA Shoe Comparison: Will Rani Therapeutics Holdings Inc. stock outperform tech sector in 2025Grip and Outsole Review & quick comparison of popular models - Улправда
HC Wainwright Reaffirms Buy Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI: HC Wainwright Reiterates Buy Rating with $11 Target | RANI Stock News - GuruFocus
Is Rani Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Summary & Consistent Return Investment Signals - Улправда
How Rani Therapeutics Holdings Inc. stock reacts to inflationary pressuresTrade Risk Report & Long-Term Investment Growth Plans - Улправда
How Rani Therapeutics Holdings Inc. stock compares to growth peersJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - Улправда
Can Rani Therapeutics Holdings Inc. stock sustain revenue growthQuarterly Profit Report & Verified Momentum Stock Alerts - Улправда
Can Rani Therapeutics Holdings Inc. stock hit record highs againQuarterly Profit Review & Growth Focused Entry Point Reports - Улправда
Aug Intraday: Is Rani Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Volume & Scalable Portfolio Growth Methods - Улправда
Rani Therapeutics begins phase 1 trial of oral obesity treatment By Investing.com - Investing.com Australia
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen - The Manila Times
Rani Therapeutics begins phase 1 trial of oral obesity treatment - Investing.com
Rani Therapeutics Initiates Phase 1 Study of RT-114 - GlobeNewswire
Can Rani Therapeutics Holdings Inc. stock rebound after recent weaknessMorning Star Patterns & Invest Now - Улправда
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Rani Therapeutics amends charter, reduces Class B voting power and ends tax agreement - Investing.com Nigeria
0.49%
2.24%
자본화:
|
볼륨(24시간):